Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.87 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.87 |
| ▸ | APP | P05067 | 4/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.64 |
| ▸ | NPC1 | O15118 | 1/20 | 0.63 |
| ▸ | MEN1 | O00255 | 4/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.61 |
| ▸ | GAA | P10253 | 2/20 | 0.61 |
| ▸ | EGFR | P00533 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.56 |
| ▸ | KCNH3 | Q9ULD8 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8973510 | 0.93 | MAPT (1.00) | MAPTSMN1; SMN2APPCYP1A2CYP3A4 | |
| SCHEMBL4544853 | 0.92 | MAPT (0.71) | MAPTSMN1; SMN2APPNPC1MEN1 | |
| SCHEMBL1390681 | 0.90 | MAPT (0.93) | MAPTSMN1; SMN2APPCYP1A2CYP3A4 | |
| SCHEMBL3501886 | 0.89 | MAPT (0.90) | MAPTSMN1; SMN2APPCYP1A2CYP3A4 | |
| SCHEMBL11785244 | 0.88 | NPC1 (0.77) | MAPTSMN1; SMN2APPCYP1A2CYP3A4 | |
| SCHEMBL20814409 | 0.87 | MAPT (0.81) | MAPTSMN1; SMN2APPCYP1A2CYP3A4 | |
| SCHEMBL28736261 | 0.87 | MAPT (0.87) | MAPTSMN1; SMN2APPCYP1A2CYP3A4 | |
| SCHEMBL3502169 | 0.87 | MAPT (0.87) | MAPTSMN1; SMN2APPCYP1A2CYP3A4 | |
| SCHEMBL10143511 | 0.86 | MAPT (0.69) | MAPTSMN1; SMN2APPCYP1A2CYP3A4 | |
| SCHEMBL12732285 | 0.85 | KCNH3 (0.68) | MAPTSMN1; SMN2NPC1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100189726-A1 | LPAAT-BETA INHIBITORS AND USES THEREOF | CELL THERAPEUTICS, INC. (US) | 2010-07-29 | — | — | US | claimed |
| US-20070072856-A1 | LPAAT-beta inhibitors and uses thereof | CELL THERAPEUTICS, INC. (US) | 2007-03-29 | — | — | US | claimed |
| US-20040162288-A1 | LPAAT-beta inhibitors and uses thereof | CELL THERAPEUTICS, INC. | 2004-08-19 | — | — | US | claimed |
| WO-2002036578-A9 | TRIAZINE DERIVATIVES AS LPAAT-B INHIBITORS AND USES THEREOF | BONHAM LYNN (US) | 2004-04-22 | — | — | WO | claimed |
| US-20030100557-A1 | LPAAT-beta inhibitors and uses thereof | CELL THERAPEUTICS, INC. | 2003-05-29 | — | — | US | claimed |
| US-20020103195-A1 | LPAAT-B inhibitors and uses thereof | CELL THERAPEUTICS,INC. | 2002-08-01 | — | — | US | claimed |
| WO-2002036578-A2 | TRIAZINE DERIVATIVES AS LPAAT-B INHIBITORS AND USES THEREOF | BONHAM LYNN (US) | 2002-05-10 | — | — | WO | claimed |
| US-20100189726-A1 | LPAAT-BETA INHIBITORS AND USES THEREOF | CELL THERAPEUTICS, INC. (US) | 2010-07-29 | — | — | US | disclosed |
| US-7608620-B2 | LPAAT-β inhibitors and uses thereof | CELL THERAPEUTICS, INC. (US) | 2009-10-27 | — | — | US | disclosed |
| US-7199238-B2 | LPAAT-β inhibitors and uses thereof | CELL THERAPUETICS, INC. (US) | 2007-04-03 | — | — | US | disclosed |
| US-20070072856-A1 | LPAAT-beta inhibitors and uses thereof | CELL THERAPEUTICS, INC. (US) | 2007-03-29 | — | — | US | disclosed |
| US-7064125-B2 | LPAAT-β inhibitors and uses thereof | CELL THERAPEUTICS, INC. (US) | 2006-06-20 | — | — | US | disclosed |
| US-20060035896-A1 | LPAAT-beta inhibitors and uses thereof | CELL THERAPEUTICS, INC. (US) | 2006-02-16 | — | — | US | disclosed |
| US-20040162288-A1 | LPAAT-beta inhibitors and uses thereof | CELL THERAPEUTICS, INC. | 2004-08-19 | — | — | US | disclosed |
| WO-2002036578-A9 | TRIAZINE DERIVATIVES AS LPAAT-B INHIBITORS AND USES THEREOF | BONHAM LYNN (US) | 2004-04-22 | — | — | WO | disclosed |
| US-20030100557-A1 | LPAAT-beta inhibitors and uses thereof | CELL THERAPEUTICS, INC. | 2003-05-29 | — | — | US | disclosed |
| US-20020103195-A1 | LPAAT-B inhibitors and uses thereof | CELL THERAPEUTICS,INC. | 2002-08-01 | — | — | US | disclosed |
| WO-2002036578-A2 | TRIAZINE DERIVATIVES AS LPAAT-B INHIBITORS AND USES THEREOF | BONHAM LYNN (US) | 2002-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060035896-A1 | LPAAT-beta inhibitors and uses thereof | LPCAT3, LPCAT1, PLAAT2 | MAPT 2134/4885SMN1; SMN2 4784/4885APP 1751/4885 |
| US-20100189726-A1 | LPAAT-BETA INHIBITORS AND USES THEREOF | LPCAT3, LPCAT1, PLAAT2 | MAPT 2807/4885SMN1; SMN2 4780/4885APP 2069/4885 |
| US-20020103195-A1 | LPAAT-B inhibitors and uses thereof | LPCAT3, LPCAT1, PLAAT2 | MAPT 3108/4885SMN1; SMN2 4809/4885APP 3583/4885 |
| US-20070072856-A1 | LPAAT-beta inhibitors and uses thereof | LPCAT3, LPCAT1, PLAAT2 | MAPT 2807/4885SMN1; SMN2 4780/4885APP 2069/4885 |
| US-20040162288-A1 | LPAAT-beta inhibitors and uses thereof | LPCAT3, LPCAT1, PLAAT2 | MAPT 2914/4885SMN1; SMN2 4791/4885APP 2444/4885 |
| US-20030100557-A1 | LPAAT-beta inhibitors and uses thereof | LPCAT3, LPCAT1, PLAAT2 | MAPT 2914/4885SMN1; SMN2 4791/4885APP 2444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.